Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00811642
First received: December 18, 2008
Last updated: July 1, 2014
Last verified: July 2014

December 18, 2008
July 1, 2014
November 2008
March 2010   (final data collection date for primary outcome measure)
Number of Participants Who Had Clinical Response at 12 Weeks With Posaconazole Treatment [ Time Frame: Treatment week 12 ] [ Designated as safety issue: No ]

EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:

Complete Response: resolution of Invasive Fungal Infection (IFI) attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.

Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.

Stable disease: no progress in IFI attributable symptoms, if present at enrollment.

Failure: deterioration in IFI attributable clinical symptoms.

Cumulative clinical effective rate at the end of POS treatment [ Time Frame: The maximum duration <=12 weeks since randomization ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00811642 on ClinicalTrials.gov Archive Site
  • Number of Participants Who Had Clinical Response at 4 Weeks With Posaconazole Treatment [ Time Frame: Treatment week 4 ] [ Designated as safety issue: No ]

    EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:

    Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.

    Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.

    Stable disease: no progress in IFI attributable symptoms, if present at enrollment.

    Failure: deterioration in IFI attributable clinical symptoms.

  • Number of Participants Who Had Clinical Response at 8 Weeks With Posaconazole Treatment [ Time Frame: Treatment week 8 ] [ Designated as safety issue: No ]

    EVALUATION OF PARTICIPANTS' CLINICAL RESPONSE BASED ON CRITERIA:

    Complete Response: resolution of IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment.

    Partial Response: clinically significant improvement in IFI attributable symptoms, signs and laboratory or etiological abnormalities, if present at enrollment, of which, one still had not achieved complete recession.

    Stable disease: no progress in IFI attributable symptoms, if present at enrollment.

    Failure: deterioration in IFI attributable clinical symptoms.

  • Number of Participants With Pathogenic Fungal Eradication at 4 Weeks With Posaconazole Treatment [ Time Frame: Treatment week 4 ] [ Designated as safety issue: No ]

    EVALUATION OF FUNGAL ERADICATION:

    Participants' mycological response to therapy was assessed by the following:

    Eradication: Negative culture or histologically documented absence of infecting

    fungal pathogen from a primary site previously positive.

    Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.

    Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.

  • Number of Participants With Pathogenic Fungal Eradication at 8 Weeks With Posaconazole Treatment [ Time Frame: Treatment week 8 ] [ Designated as safety issue: No ]

    EVALUATION OF FUNGAL ERADICATION:

    Participants' mycological response to therapy was assessed by the following:

    Eradication: Negative culture or histologically documented absence of infecting

    fungal pathogen from a primary site previously positive.

    Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.

    Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.

  • Number of Participants With Pathogenic Fungal Eradication at 12 Weeks With Posaconazole Treatment [ Time Frame: Treatment week 12 ] [ Designated as safety issue: No ]

    EVALUATION OF FUNGAL ERADICATION:

    Participants' mycological response to therapy was assessed by the following:

    Eradication: Negative culture or histologically documented absence of infecting

    fungal pathogen from a primary site previously positive.

    Presumed Eradication: Resolution of all IFI attributable symptoms, signs and laboratory or radiological abnormalities in which a repeat culture/biopsy was contraindicated.

    Persistence: Continued isolation of fungal pathogen from a primary site previously positive or cytological documentation of presence of fungal pathogen.

  • Number of Participant Survivors at Week 14 of Post-Posaconazole Treatment Follow-up [ Time Frame: Follow-up week 14 ] [ Designated as safety issue: No ]
    Total number of participant deaths was assessed at the end of 2 week post-treatment follow-up (14 weeks). The total number of deaths was compared to the number of survivors at baseline.
  • Cumulative clinical effective rate at 4W, 8W of POS treatment [ Time Frame: The maximum duration <=12 weeks since randomization ] [ Designated as safety issue: No ]
  • Cumulative pathogenic fungal eradication rate at 4W, 8W and the end of POS treatment [ Time Frame: The maximum duration <=12 weeks since randomization ] [ Designated as safety issue: No ]
  • Cumulative survival rate at the end of POS treatment [ Time Frame: The maximum duration <=12 weeks since randomization ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection

The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Fungal Infection
Drug: Posaconazole
400mg BID oral suspension for 12 weeks
Other Name: Noxafil
Experimental: Posaconazole
Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
Intervention: Drug: Posaconazole
Huang X, Wang F, Chen Y, Liu T, Wang J, Hu J, Jie J, Chen F, Wang S, Shen Z, Yu L, Yu K, Liang Y. A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy. Future Microbiol. 2012 Feb;7(2):201-9. doi: 10.2217/fmb.11.158.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
63
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants must be 18-70 years male or female
  • Identified or clinically diagnosed IFI participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment.
  • Sign informed consent form

Exclusion Criteria:

  • Female participants who are pregnant or are nursing.
  • Participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin B
  • Participants with progressive nervous system diseases( excluding those IFI caused)
  • Participants who take the following drugs known with interference with azole antifungal preparations

    • terfenadine, cisapride, and ebastine within 24 hours before entry
    • astemizole at entry or within 10 days before entry
    • cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry
  • The drugs listed above are prohibited during the investigation
  • Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate <60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities.
  • Participants having an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.
  • Expected to take during investigation or is taking systemic antifungal treatment
  • Participants with severe renal insufficiency (estimated creatinine clearance less than 50 mL/minute or likely to require dialysis during the study), ALT,AST AKP or total bilirubin are >2×ULN.
  • Participants expected to survive no more than 72hrs
  • Participants receiving artificial aeration and will not withdraw within 24hrs
  • Participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry.
  • Prior enrollment in this study.
  • History of alcohol and/or drug abuse.
  • Participants cannot be compliant in investigator's opinion.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00811642
P05551
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP